Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31166967 | 0.85 | MAPT (0.49) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL1961466 | 0.85 | MAPT (0.55) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL3189109 | 0.82 | MAPT (0.72) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL29378830 | 0.82 | MAPT (0.72) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL1988162 | 0.81 | MAPT (0.51) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL7482250 | 0.81 | MAPT (0.51) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL17142284 | 0.80 | ALDH1A1 (0.54) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL4143348 | 0.79 | MAPT (0.68) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| 2-Hydroxy-3,4-Dimethoxybenzoic Acid SCHEMBL419244 | 0.79 | MAPT (1.00) | MAPTTDP1MAPK1KDM4EHSD17B10 | |
| SCHEMBL15524603 | 0.78 | LCK (0.50) | MAPTTDP1MAPK1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-14 | — | — | US | disclosed |
| US-20170027921-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-02 | — | — | US | disclosed |
| WO-2016208775-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376244-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9518042-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-13 | — | — | US | disclosed |
| US-9499516-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9315458-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| WO-2015163485-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 172/4885TDP1 1457/4885MAPK1 603/4885 |
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | CHRM1, CHRM4, CHRM2 | MAPT 166/4885TDP1 1413/4885MAPK1 1210/4885 |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 172/4885TDP1 1457/4885MAPK1 603/4885 |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 172/4885TDP1 1457/4885MAPK1 603/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | MAPT 326/4885TDP1 1696/4885MAPK1 829/4885 |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 172/4885TDP1 1457/4885MAPK1 603/4885 |
| US-20170027921-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 172/4885TDP1 1457/4885MAPK1 603/4885 |
| US-20160376244-A1 | HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 121/4885TDP1 1626/4885MAPK1 773/4885 |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRNA5 | MAPT 150/4885TDP1 2165/4885MAPK1 897/4885 |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | MAPT 1794/4885TDP1 2464/4885MAPK1 2338/4885 |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | BCL6, BCL6B, BCL3 | MAPT 1794/4885TDP1 2464/4885MAPK1 2338/4885 |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPT 172/4885TDP1 1457/4885MAPK1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.